A role for thrombin in liver fibrosis
View abstract on PubMed
Summary
This summary is machine-generated.Thrombin inhibition with SSR182289 reduced experimental liver fibrosis in rats, particularly after seven weeks of carbon tetrachloride exposure. Early treatment also decreased fibrogenic cell activation markers.
Area Of Science
- Hepatology
- Fibrosis Research
- Pharmacology
Background
- Thrombin, a serine proteinase, is implicated in liver fibrogenesis via procoagulant functions and receptor signaling.
- Experimental models are crucial for understanding liver fibrosis mechanisms.
Purpose Of The Study
- To investigate the therapeutic effect of thrombin inhibition on experimental liver fibrosis.
- To evaluate the impact of a thrombin antagonist on fibrotic markers and gene expression.
Main Methods
- Carbon tetrachloride (CCl4) induced liver fibrosis in rats over three or seven weeks.
- Oral administration of thrombin antagonist SSR182289.
- Histomorphometry quantified fibrosis and alpha smooth muscle actin (ASMA) positive areas.
- Real-time RT-PCR measured fibrosis-related gene expression.
Main Results
- After three weeks, SSR182289 significantly reduced ASMA positive cells (-22%) and TIMP-1 mRNA expression (-52%), but not overall fibrosis.
- After seven weeks, SSR182289 significantly decreased fibrosis (-30%) and ASMA positive areas (-35%).
- No effect on acute CCl4 toxicity markers (serum aminotransferases, necrosis).
Conclusions
- Thrombin antagonism demonstrates potential in reducing liver fibrogenesis.
- Early intervention with SSR182289 may mitigate fibrogenic cell activation, indicated by ASMA and TIMP-1 modulation.